CIMT 2024: Report on the 21st Annual Meeting of the Association for Cancer Immunotherapy
The 21st Association for Cancer Immunotherapy (CIMT) Annual Meeting took place from May 15th to May 17th in Mainz, Germany, and was attended by a total of 855 academic and clinical professionals hailing from 33 different countries. The conference served as a platform for these experts to convene and...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/21645515.2024.2381925 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849737985337065472 |
|---|---|
| author | Yasemin Ahrberg Julia Dallmann Janina Freitag Abdulrizak Hassan Christina Jung Johanna Kiefer Anindhita Meena Muralidharan Matthias Peter Jan D. Beck |
| author_facet | Yasemin Ahrberg Julia Dallmann Janina Freitag Abdulrizak Hassan Christina Jung Johanna Kiefer Anindhita Meena Muralidharan Matthias Peter Jan D. Beck |
| author_sort | Yasemin Ahrberg |
| collection | DOAJ |
| description | The 21st Association for Cancer Immunotherapy (CIMT) Annual Meeting took place from May 15th to May 17th in Mainz, Germany, and was attended by a total of 855 academic and clinical professionals hailing from 33 different countries. The conference served as a platform for these experts to convene and discuss the latest breakthroughs in cancer immunology and immunotherapy research. Dedicated sessions covering advancements in artificial intelligence tools for cancer immunotherapy research, as well as the landscape of cancer care and cancer immunotherapy trials on the African continent, prompted lively and informative discussions among the attendees. This report aims to provide an overview of the most noteworthy highlights and key takeaways from CIMT2024. |
| format | Article |
| id | doaj-art-eb21e4289c594e49b599fa135ecea5a6 |
| institution | DOAJ |
| issn | 2164-5515 2164-554X |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj-art-eb21e4289c594e49b599fa135ecea5a62025-08-20T03:06:44ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2024-12-0120110.1080/21645515.2024.2381925CIMT 2024: Report on the 21st Annual Meeting of the Association for Cancer ImmunotherapyYasemin Ahrberg0Julia Dallmann1Janina Freitag2Abdulrizak Hassan3Christina Jung4Johanna Kiefer5Anindhita Meena Muralidharan6Matthias Peter7Jan D. Beck8TRON-Translational Oncology, University Medical Center of Johannes Gutenberg University Mainz gGmbH, Mainz, GermanyBioNTech SE, Mainz, GermanyTRON-Translational Oncology, University Medical Center of Johannes Gutenberg University Mainz gGmbH, Mainz, GermanyBioNTech SE, Mainz, GermanyBioNTech Cell & Gene Therapies GmbH, Mainz, GermanyBioNTech SE, Mainz, GermanyTRON-Translational Oncology, University Medical Center of Johannes Gutenberg University Mainz gGmbH, Mainz, GermanyTRON-Translational Oncology, University Medical Center of Johannes Gutenberg University Mainz gGmbH, Mainz, GermanyBioNTech SE, Mainz, GermanyThe 21st Association for Cancer Immunotherapy (CIMT) Annual Meeting took place from May 15th to May 17th in Mainz, Germany, and was attended by a total of 855 academic and clinical professionals hailing from 33 different countries. The conference served as a platform for these experts to convene and discuss the latest breakthroughs in cancer immunology and immunotherapy research. Dedicated sessions covering advancements in artificial intelligence tools for cancer immunotherapy research, as well as the landscape of cancer care and cancer immunotherapy trials on the African continent, prompted lively and informative discussions among the attendees. This report aims to provide an overview of the most noteworthy highlights and key takeaways from CIMT2024.https://www.tandfonline.com/doi/10.1080/21645515.2024.2381925CIMTcancer immunotherapyartificial intelligencecellular therapycombination therapytumor microenvironment |
| spellingShingle | Yasemin Ahrberg Julia Dallmann Janina Freitag Abdulrizak Hassan Christina Jung Johanna Kiefer Anindhita Meena Muralidharan Matthias Peter Jan D. Beck CIMT 2024: Report on the 21st Annual Meeting of the Association for Cancer Immunotherapy Human Vaccines & Immunotherapeutics CIMT cancer immunotherapy artificial intelligence cellular therapy combination therapy tumor microenvironment |
| title | CIMT 2024: Report on the 21st Annual Meeting of the Association for Cancer Immunotherapy |
| title_full | CIMT 2024: Report on the 21st Annual Meeting of the Association for Cancer Immunotherapy |
| title_fullStr | CIMT 2024: Report on the 21st Annual Meeting of the Association for Cancer Immunotherapy |
| title_full_unstemmed | CIMT 2024: Report on the 21st Annual Meeting of the Association for Cancer Immunotherapy |
| title_short | CIMT 2024: Report on the 21st Annual Meeting of the Association for Cancer Immunotherapy |
| title_sort | cimt 2024 report on the 21st annual meeting of the association for cancer immunotherapy |
| topic | CIMT cancer immunotherapy artificial intelligence cellular therapy combination therapy tumor microenvironment |
| url | https://www.tandfonline.com/doi/10.1080/21645515.2024.2381925 |
| work_keys_str_mv | AT yaseminahrberg cimt2024reportonthe21stannualmeetingoftheassociationforcancerimmunotherapy AT juliadallmann cimt2024reportonthe21stannualmeetingoftheassociationforcancerimmunotherapy AT janinafreitag cimt2024reportonthe21stannualmeetingoftheassociationforcancerimmunotherapy AT abdulrizakhassan cimt2024reportonthe21stannualmeetingoftheassociationforcancerimmunotherapy AT christinajung cimt2024reportonthe21stannualmeetingoftheassociationforcancerimmunotherapy AT johannakiefer cimt2024reportonthe21stannualmeetingoftheassociationforcancerimmunotherapy AT anindhitameenamuralidharan cimt2024reportonthe21stannualmeetingoftheassociationforcancerimmunotherapy AT matthiaspeter cimt2024reportonthe21stannualmeetingoftheassociationforcancerimmunotherapy AT jandbeck cimt2024reportonthe21stannualmeetingoftheassociationforcancerimmunotherapy |